Alabama Clinical Trials Report — June 2026

For Alabamians considering participation in clinical research, June 2026 brings a wave of new opportunities, but also a critical window for trials nearing their conclusion. Across the state, 68 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 15 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cancers and heart conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Astrocytoma
• Endometrial cancer
• Fallopian tube cancer
• Ovarian cancer
• Heart failure
• Glioblastoma multiforme
• Breast cancer
• Astrocytoma, cerebellar
• Autism
• Adverse birth outcomes

Major Research Initiatives Launch Across Alabama

This month, Alabama welcomes 26 new clinical trials, a notable increase from the 21 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity and type 2 diabetes, as well as crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron.
• Pfizer is leading two important Phase 3 vaccine trials. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662109, a Phase 3 study investigating "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial plans for 2,000 participants. Another AstraZeneca Phase 3 study, NCT07662213, will compare elecoglipron with oral semaglutide in 1,200 adults with type 2 diabetes and increased cardiovascular risk.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants.
• The University of Alabama at Birmingham is sponsoring NCT07671937, "INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study," which plans to enroll 2,748 participants to characterize baseline multidisciplinary tumor board context and evaluate the impact of including patient-reported evaluations.

New Research Opportunities Across Conditions and Interventions

The 26 new trials opening this month in Alabama cover a diverse range of health conditions, with a strong focus on metabolic health and infectious disease prevention. The most common conditions addressed by these new studies include:

• Obesity (4 trials)
• Overweight (3 trials)
• Type 2 diabetes mellitus (3 trials)
• Pneumococcal disease (2 trials)
• Hypertension (2 trials)
• Chronic weight management (2 trials)
• Chronic pain (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 15 of the new studies. Behavioral interventions are also well-represented with 7 new trials, alongside other types of research including biological treatments and dietary supplements.

Geographic Reach: Birmingham Leads, Other Cities Expand Access

Alabama's clinical research landscape continues to be robust, with 1,206 clinical trials currently recruiting across 38 cities and 581 research sites statewide. This month, the majority of new research initiatives are concentrated in the Birmingham metropolitan area, which saw 21 new trials open. However, opportunities are also expanding in other parts of the state:

• Mobile (2 new trials)
• Auburn (2 new trials)
• Montgomery (1 new trial)
• Huntsville (1 new trial)
• Daphne (1 new trial)
• Jacksonville (1 new trial)

This distribution ensures that residents in various regions of Alabama have access to cutting-edge research, even as Birmingham remains a central hub for clinical investigations.

Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 26 new trials launched this month, 6 are actively seeking healthy volunteers. Statewide, a total of 151 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Alabama are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 2 include children as participants, and 22 include older adults, ensuring that research benefits diverse age groups. Academic institutions continue to play a vital role in the state's research ecosystem, with the University of Alabama at Birmingham sponsoring 7 of the new trials. Industry sponsors are also driving significant research efforts, with 16 new trials sponsored by pharmaceutical companies such as AstraZeneca, Kallyope Inc., Novo Nordisk A/S, Pfizer, Gasherbrum Bio, Inc., and Eli Lilly and Company.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Alabama.